Studies have investigated the relationship between genetic variants and risk of gestational diabetes mellitus (GDM). However, the results remain inconclusive. The aim of this study was to investigate the association of rs10830963 and rs1387153 variants in melatonin receptor 1B (MTNR1B) and rs1801278 variant in insulin receptor substrate 1 (IRS1) with GDM susceptibility. Electronic database of PubMed, Medline, Embase, and CNKI (China National Knowledge Infrastructure) were searched for relevant studies between 2005 and 2014. The odds ratio (OR) with its 95% confidence interval (CI) were employed to estimate the association. Total ten case-control studies, including 3428 GDM cases and 4637 healthy controls, met the inclusion criteria. Our results showed a significant association between the three genetic variants and GDM risk, rs10830963 with a P-value less than 0.0001, rs1387153 with a P-value of 0.0002, and rs1801278 with a P-value of 0.001. Furthermore, all the genetic models in these three polymorphisms were associated with increased risks of GDM as well (P,50.009). In conclusion, our study found that the genetic polymorphisms rs10830963 and rs1387153 in MTNR1B and rs1801278 in IRS1 were associated with an increased risk of developing GDM. However, further studies with gene-gene and gene-environmental interactions should be considered.
G estational diabetes mellitus (GDM), defined as glucose intolerance with onset or first recognition during pregnancy, is one of the most common medical problems and a growing public health concern 1, 2 . It causes by an increase in the insulin resistance, and the condition is also aggravated by insulin secretion from the b cells of the pancreas 3 . GDM affects 1-14% of all pregnant women depending on the population studied 4 : it complicates about 1-3% of all pregnancies in the western world 5 , whereas 5-10% among Asian women 6 . GDM is often more common in populations with a high frequency of type 2 diabetes (T2D) 7 . Furthermore, it increases risk of adverse pregnancy outcomes and has substantial long-term adverse health impacts on both mothers and their offspring. Though the WHO current guidelines for GDM were published in 1999 and are widely used worldwide 8 , to date, there is still no universal recommendation for the ideal approach for screening and diagnosis of GDM. Thus, identifying patients at a higher risk of GDM has become an important goal.
Recently, extraordinary progress was made in identifying susceptible genes of complicated diseases through genome-wide association strategy 9, 10 . Melatonin receptor 1B (MTNR1B) and insulin receptor substrate 1 (IRS1) were two of diabetogenic genes associated with the developing of GDM. Melatonin is a circulating hormone secreted mainly from the pineal gland 11 , and acts mostly through G-protein-coupled plasma membrane receptors 12 . MTNR1B, located on human chromosome 11q21-22 13 , is a member of the G-protein-coupled receptor family, and one of the functional and high-affinity melatonin membrane receptors 14 . MTNR1B is expressed in human and rodent pancreatic islets. Studies have shown that MTNR1B is a novel candidate gene for T2D , is expressed in insulin-sensitive tissues. It is an endogenous substrate of the insulin receptor 18 , and plays a crucial role in the insulin signaling pathway. The IRS1 gene variant rs1801278, a nucleotide T/C substitution in codon 972 (Gly972Arg), has been identified to be associated with increased risk of T2D and GDM 19 . Although numerous studies have demonstrated the association between genetic polymorphisms and the developing of GDM, inconsistent results were presented for each polymorphism among study populations. The purpose of this meta-analysis is to summarize the existing evidence on the prevalence of the genetic polymorphisms in patients diagnosed with GDM.
Results
Study selection and characteristics. The electronic database search identified 107 references. After applying the inclusion criteria, 10 articles including 3428 GDM cases and 4637 healthy controls were ultimately included in the systematic review and meta-analysis. The study selection process is shown in Figure 1 .
All the 10 reports, one in Chinese 20 and nine in English [21] [22] [23] [24] [25] [26] [27] [28] [29] , included cases and controls from 7 countries concerning 3 genetic variants in 2 genes (MTNR1B and IRS1). The detailed characteristics of the studies included were shown in Table 1 . The distributions of genotypes and alleles in the individual studies were presented in Table 2 .
Association between MTNR1B rs10830963 variant and GDM. For MTNR1B rs10830963 variant, five studies, containing 2122 GDM cases and 2664 healthy controls, were included. The results of each allele and genetic models in this meta-analysis were listed in Table S1 . The heterogeneity between studies was assessed, and the fixed-effects model and the random-effects model were employed for calculating the pooled odds ratio (OR). Overall, this meta-analysis showed that the frequency of MTNR1B rs10830963 G allele is higher in GDM patients than that in the healthy controls (48.4% vs. 42.3%), and Figure 5 ). No significant heterogeneity was found between these two studies (I 2 50%).
Association between IRS1 rs1801278 variant and GDM. The association between rs1801278 and GDM has been examined in five studies, including 1306 GDM cases and 1973 controls. Our meta-analysis of these studies showed that the frequency of the T allele of rs1801278 was higher in GDM than that in controls (8.7% vs. 5.1%), and indicated a significant association with an increased risk of GDM (OR51.42, 95% CI51.15-1.75, P50.001) ( Figure 6 ). As shown in Figure 7 and Figure S1 , the dominant model and recessive model were also significant with GDM susceptibility, Sensitivity analysis and publication bias. The influence of each study on the overall meta-analysis estimate was assessed by eliminating one study at a time, respectively. The OR was not significantly influenced by omitting any single study. Begger's funnel plot was used to identify individual studies in relation to their respective standard deviation, as shown in Figure 8 and Figure S2 , which revealed no evidence of asymmetry. Egger's test was employed to provide further statistical evidence, similarly, no significant publication bias was found for all these three polymorphisms (P50.263 for MTNR1B rs10830963, P50.378 for MTNR1B rs1387153, P50.149 for IRS1 rs1801278). Thus, there does not appear to be a publication bias risk in the meta-analysis.
Discussion
GDM is usually recognized as a temporary form of diabetes that occurs during pregnancy, and is associated with an increased risk of complications during pregnancy and birth 30 . Women with GDM are at a high risk of developing T2D later in life 31 , and the risk of developing type 1 diabetes (T1D) is also increased 32 . Moreover, GDM increases the risk of macrosomia and caesarean delivery 33 . Therefore, there is an urgent need to study the pathogenesis and establish diagnosis criteria for GDM.
Many studies have shown that gene polymorphisms could provide insight into underlying pathogenetic mechanisms and the relationship between candidate genes and complex diseases. Functional studies showed that those diabetogenic genes took part in many steps of the process of developing GDM. For instance, impaired b-cell function (MTNR1B), insulin resistance (IRS1), and abnormal utilization of glucose. In our meta-analysis, we found that the frequency GC  CC  G  C  GG  GC  CC  G  C  Deng  26  38  23  90  84  15  45  31  75  107  Kim  256  435  217  947  869  203  469  294  875  1057  Wang  137  364  199  638  762  191  509  329  891  1167  Vlassi  16  31  30  63  91  12  30  56  54  142  Li  79  158  113  316  384  75  233  172  383  577  MTNR1B rs1387153 (C/T)  TT  TC  CC  T  C  TT  TC  CC  T  C  Kim  241  433  235  915  903  204  455  313  863  1081  Vlassi  12  26  39  50  104  11  35  52  57  139  IRS1 rs1801278 (C/T)  TT  TC  CC  T  C  TT  TC  CC  T  C  Shaat  4  49  534  57  1117  0  111  1078  111 of G allele in rs10830963, and T alleles in both rs1387153 and rs1801278 respectively, were higher in GDM cases than that in healthy controls, demonstrating strong statistical association with an increased risk of GDM. GDM is associated with both insulin resistance and an impaired insulin secretion 34 . GDM could develop when a genetic predisposition of pancreatic islet b-cell impairment is unmasked by an increased insulin resistance during pregnancy 35 . MTNR1B variants are related to insulin secretion and impaired b-cell function. Liao et al. have showed that MTNR1B is likely to be involved in the regulation of glucose homeostasis during pregnancy 36 . MTNR1B rs10830963 has been shown to influence the fasting plasma glucose (FPG) 37 and to be associated with T2D 38 ; rs1387153 has been reported to be associated with an increased FPG and a higher risk of T2D 39 . In our study, we found that the SNPs rs1387153 and rs10830963 in MTNR1B occur more frequently in women with GDM than in normal pregnant women, supporting a potential association of these polymorphisms with an increased risk of developing GDM. This may due to the observation that MTNR1B down-regulates GCK expression and glucose-stimulated insulin secretion by lowering intracellular cAMP level 40 . An increased expression of MTNR1B on b-cells leads to impaired insulin secretion. Previous studies have shown that the G allele of rs10830963 polymorphism in the MTNR1B exhibits a higher expression of this melatonin receptor on the b-cell as compared with that of the C allele 41 .
IRS1, a substrate of the insulin receptor tyrosine kinase and a participant in insulin signaling 42 , is related to insulin resistance. It plays a crucial role in the signal transduction pathway 43 . Epidemiological studies confirmed that the prevalence of GDM is in direct proportion to the prevalence of T2D. A meta-analysis conducted by Jellema et al. has shown that carriers of the R972 variant of the IRS1 gene are at a 25% increased risk of having T2D compared with non-carriers 44 . While Morini et al. investigating 32 studies found that the relatively infrequent R972 variant was not significantly associated with T2D 45 . Our result showed a significant association between IRS1 rs1801278 polymorphism and GDM risk. IRS1 protein is expressed in many insulin-sensitive tissues, and its tyrosine phosphorylation can elicit the downstream effects of insulin, such as activation of phosphatidylinositol 3-kinase (PI3K) and translocation of glucose transporter 4 46 . Previous studies have shown that the IRS1 G972R polymorphism, which reduces insulin content and impairs insulin secretion in isolated human islets, is associated with impaired b-cell function 29 . Evidence suggests that susceptibility to GDM has a genetic component, family studies indicate that GDM aggregates within families and is associated with a history of T2D 47 . Several limitations were presented in this meta-analysis. Firstly, the number of studies included was relatively small. For MTNR1B rs1387153 variant, only two studies were included. Secondly, studies were mainly focused on Asian populations or Caucasian populations, other populations should also be included. Thirdly, these poly- morphisms may interact with other risk factors which should be considered. Fourthly, the selected studies could be more subject to bias and artifact than prospective studies.
In conclusion, our meta-analysis demonstrated that genetic polymorphisms rs10830963 and rs1387153 in MTNR1B and rs1801278 in IRS1 were associated with an increased risk of developing GDM. However, further studies with large sample sizes and accounting for the interaction of genetic and environmental risk factors are needed to understand associations between the genetic polymorphisms and risk of GDM.
Methods
Identification and eligibility of relevant studies. A comprehensive literature search was conducted for relevant articles published between January 2005 and March 2014 using the electronic database of PubMed, Medline, Embase, Wanfang and CNKI (China National Knowledge Infrastructure). We retrieved the related articles using the following terms: ''gestational diabetes mellitus'', ''melatonin receptor 1B or MTNR 1B'', ''insulin receptor substrate 1 or IRS1'', ''polymorphisms or variants'' as well as their combinations. The corresponding Chinese terms were used in the Chinese library. References of retrieved articles were searched with no language restrictions. The search was focused on studies that had been conducted in humans. Only full-text articles and the most recent studies were included in this meta-analysis.
Criteria for inclusion. The inclusion criteria were as follows: 1) the paper should be case-control or cohort studies; 2) identification of gestational diabetes mellitus cases was confirmed pathologically and the controls should be non-diabetic; 3) each study included at least one of the three polymorphisms, rs10830963 and rs1387153 in MTNR1B, rs1801278 in IRS1; 4) genotype distribution information and OR with its 95% CI were available; and 5) genotype distribution of control for a certain polymorphism must be in Hardy-Weinberg equilibrium.
Data extraction. Two investigators independently assessed the quality of the included studies according to the descriptions provided by the authors of the included studies. Any disagreement was subsequently resolved by discussion with a third author. The following information was extracted from each article: first author, year of publication, country, ethnicity, mean age, body mass index (BMI), total numbers, definition and genotype distributions in GDM cases and controls.
Statistical analysis. The overall association between genetic polymorphisms and GDM risk was measured by OR and its 95% CI. The Z test was employed to determine the significance of the pooled ORs, and a P value less than 0.05 was considered statistically significant. For rs10830963, the allelic model (G vs. C) and genotype genetic models (co-dominant effects: GG vs. CC; dominant effect: GG1GC vs. CC; and recessive effect: GG vs. GC1CC) were examined; for rs1387153 and rs1801278, the allelic model (T vs. C) and genotype genetic models (co-dominant effects: TT vs. CC; dominant effect: TT1TC vs. CC; and recessive effect: TT vs. TC1CC) was identified. The I 2 test was used to assess the proportion of statistical heterogeneity and the Q-statistic test was used to define the degree of heterogeneity. A P-value less than 0.10 for the Q-test and I 2 more than 50% was considered significant among the studies. Data were combined using both a fixed-effects model (the inverse varianceweighted method) and a random-effects model (DerSimonian and Laird method) 48, 49 .
The fixed-effects model is used when the effects are assumed to be homogenous, while the random-effects model is used when they are heterogenous. The evidence of publication bias was assessed by visual funnel plot inspection. Egger's regression test was also conducted to identify study effects (P-value less than 0.10 was considered significant). To evaluate whether our results were influenced by the presence of any individual study, we conducted a sensitivity analysis by systematically removing each study and reassessing the significance of the result. Statistical analyses were conducted in Review Manager (RevMan version 5.2, the Cochrane Collaboration, Oxford, England; available at: http://ims.cochrane.org/revman). All the tests were two-sided.
